Cargando…
Systematic identification of the interventional mechanism of Qingfei Xiaoyan Wan (QFXYW) in treatment of the cytokine storm in acute lung injury using transcriptomics-based system pharmacological analyses
CONTEXT: Acute lung injury (ALI) is a complex, severe inflammation disease with high mortality, and there is no specific and effective treatment for ALI. Qingfei Xiaoyan Wan (QFXYW) has been widely used to treat lung-related diseases for centuries. OBJECTIVE: This study evaluates the potential effec...
Autores principales: | Hou, Jing-Yi, Wu, Jia-Rong, Chen, Yi-Bing, Xu, Dong, Liu, Shu, Shang, Dan-dan, Fan, Guan-Wei, Cui, Yuan-Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979529/ https://www.ncbi.nlm.nih.gov/pubmed/35357989 http://dx.doi.org/10.1080/13880209.2022.2055090 |
Ejemplares similares
-
Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation
por: Zhao, Zhenying, et al.
Publicado: (2013) -
Searching for Synergistic Bronchodilators and Novel Therapeutic Regimens for Chronic Lung Diseases from a Traditional Chinese Medicine, Qingfei Xiaoyan Wan
por: Hou, Yuanyuan, et al.
Publicado: (2014) -
Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa–induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways
por: Hou, Yuanyuan, et al.
Publicado: (2016) -
Clinical efficacy evaluation and potential mechanism prediction on Pudilan Xiaoyan oral liquid in treatment of mumps in children based on meta-analysis, network pharmacology, and molecular docking
por: Liu, Yi, et al.
Publicado: (2022) -
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo
por: Deng, Wei, et al.
Publicado: (2020)